Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunotherapy. 2010 Sep;2(5):655-61. doi: 10.2217/imt.10.53.

Therapeutic targeting of respiratory syncytial virus G-protein.

Author information

1
Trellis Bioscience, 2-B Corporate Drive, South San Francisco, CA 94080, USA. lkauvar@trellisbio.com

Abstract

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in infants and young children and an important pathogen of the elderly and immune suppressed. The only intervention currently available is a monoclonal antibody against the RSV fusion protein, which has shown utility as a prophylactic for high-risk premature infants, but which has not shown postinfection therapeutic efficacy in the specific RSV-infected populations studied. Thus, for the major susceptible populations, there remains a great need for effective treatment. Recent results support monoclonal antibody targeting of the RSV G-protein for therapeutic use. This objective encompasses a dual mechanism: reduction in the ability of RSV G-protein to distort the host innate immune response, and direct complement-mediated antiviral activity.

PMID:
20874649
PMCID:
PMC3044486
DOI:
10.2217/imt.10.53
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center